title: The treatment of epithelial ovarian cancer.
abstract: The treatment and long-term survival of patients with ovarian cancer varies by stage. At present, five-year survival for patients with early-stage disease ranges from 50 to 95 percent, while five-year survival for patients with advanced-stage disease is less than 25 percent. Several new drugs with significant activity in advanced-stage ovarian cancer offer hope for increased long-term survival in the future. This article reviews the current and experimental approaches to the treatment of all stages of ovarian cancer.
authors.affiliation: Division of Hematology/Oncology, Emory University School of Medicine Atlanta, Georgia.
authors.forename: F
authors.initials: F
authors.lastname: Qazi
authors.forename: W P
authors.initials: WP
authors.lastname: McGuire
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D016879:Salvage Therapy; D016896:Treatment Outcome